Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies

Drug Resistance Updates

Volumn 9, Issue 4-5, 2006, Pages 185-197

  Magagnin, Michaël G ^a   Koritzinsky, Marianne ^a   Wouters, Bradly G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anoxia; HIF; Hypoxia; Reoxygenation; Tumor microenvironment; UPR

Indexed keywords

ECHINOMYCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NSC 13502;

ARTICLE; CELL HYPOXIA; DRUG TARGETING; HUMAN; MICROENVIRONMENT; NONHUMAN; OXYGEN SENSING; PRIORITY JOURNAL; REOXYGENATION; RNA TRANSLATION; TISSUE OXYGENATION; TUMOR GROWTH; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; NEOPLASMS; OXYGEN; OXYGEN CONSUMPTION;

EID: 33751249607     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2006.07.002     Document Type: Article

References (122)

1. Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L., et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 8 (2005) 131-141
2. Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., Patterson A., Hunter R., Stratford I., and West C. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 7 (2001) 928-934
3. Ameri K., Lewis C.E., Raida M., Sowter H., Hai T., and Harris A.L. Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 103 (2004) 1876-1882
4. Andrei M.A., Ingelfinger D., Heintzmann R., Achsel T., Rivera-Pomar R., and Luhrmann R. A role for eIF4E and eIF4E-transporter in targeting mRNPs to mammalian processing bodies. Rna 11 (2005) 717-727
5. Berra E., Ginouves A., and Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 7 (2006) 41-45
6. Bert A.G., Grepin R., Vadas M.A., and Goodall G.J. Assessing IRES activity in the HIF-1{alpha} and other cellular 5′ UTRs. Rna 12 (2006) 1074-1083
7. Bertolotti A., Zhang Y., Hendershot L.M., Harding H.P., and Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2 (2000) 326-332
8. Bi M., Naczki C., Koritzinsky M., Fels D., Blais J., Hu N., et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24 (2005) 3470-3481
9. Blais J.D., Filipenko V., Bi M., Harding H.P., Ron D., Koumenis C., Wouters B.G., and Bell J.C. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol. Cell. Biol. 24 (2004) 7469-7482
10. Blancher C., Moore J.W., Talks K.L., Houlbrook S., and Harris A.L. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60 (2000) 7106-7113
11. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
12. Boudeau J., Sapkota G., and Alessi D.R. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett. 546 (2003) 159-165
13. Boyce M., Bryant K.F., Jousse C., Long K., Harding H.P., Scheuner D., Kaufman R.J., Ma D., Coen D.M., Ron D., and Yuan J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307 (2005) 935-939
14. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., and Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56 (1996) 941-943
15. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004) 437-447
16. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18 (2004) 2893-2904
17. Cardenas-Navia L.I., Yu D., Braun R.D., Brizel D.M., Secomb T.W., and Dewhirst M.W. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res. 64 (2004) 6010-6017
18. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
19. Catley L., Tai Y.T., Chauhan D., and Anderson K.C. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist. Updat. 8 (2005) 205-218
20. Chang A.Y., Kim H., Boucher H., Bonomi P., Stewart J.A., Karp D.D., and Blum R.H. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer 82 (1998) 292-300
21. Chi J.T., Wang Z., Nuyten D.S., Rodriguez E.H., Schaner M.E., Salim A., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3 (2006) pe47
22. Connolly E., Braunstein S., Formenti S., and Schneider R.J. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol. Cell. Biol. 26 (2006) 3955-3965
23. Corradetti M.N., Inoki K., Bardeesy N., DePinho R.A., and Guan K.L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18 (2004) 1533-1538
24. Cullinan S.B., Zhang D., Hannink M., Arvisais E., Kaufman R.J., and Diehl J.A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol. 23 (2003) 7198-7209
25. Dayan F., Roux D., Brahimi-Horn M.C., Pouyssegur J., and Mazure N.M. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 66 (2006) 3688-3698
26. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
27. Deng J., Lu P.D., Zhang Y., Scheuner D., Kaufman R.J., Sonenberg N., Harding H.P., and Ron D. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol. Cell. Biol. 24 (2004) 10161-10168
28. Dong D., Dubeau L., Bading J., Nguyen K., Luna M., Yu H., Gazit-Bornstein G., Gordon E.M., Gomer C., Hall F.L., Gambhir S.S., and Lee A.S. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. Hum. Gene Ther. 15 (2004) 553-561
29. Dong Z., and Wang J. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J. Biol. Chem. 279 (2004) 9215-9221
30. Durand R.E., and Aquino-Parsons C. Clinical relevance of intermittent tumour blood flow. Acta Oncol. 40 (2001) 929-936
31. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
32. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., and Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
33. Evans S.M., Hahn S.M., Magarelli D.P., and Koch C.J. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am. J. Clin. Oncol. 24 (2001) 467-472
34. Feldman D.E., Chauhan V., and Koong A.C. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol. Cancer Res. 3 (2005) 597-605
35. Foster B.J., Clagett-Carr K., Shoemaker D.D., et al. Echinomycin: the first bifunctional intercalating agent in clinical trials. Invest. New Drugs 3 (1985) 403-410
36. Gingras A.C., Raught B., Gygi S.P., et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15 (2001) 2852-2864
37. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., and Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
38. Graff J.R., and Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metastasis 20 (2003) 265-273
39. Grau C., and Overgaard J. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ. Cancer Chemother. Pharmacol. 30 (1992) 277-280
40. Haghighat A., Mader S., Pause A., and Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 14 (1995) 5701-5709
41. Hammond E.M., Dorie M.J., and Giaccia A.J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278 (2003) 12207-12213
42. Hansen P.R. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91 (1995) 1872-1885
43. Harding H.P., Zhang Y., Zeng H., Novoa I., Lu P.D., Calfon M., et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11 (2003) 619-633
44. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
45. Hirst D.G., Denekamp J., and Hobson B. Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell Tissue Kinet. 15 (1982) 251-261
46. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56 (1996) 4509-4515
47. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23 (2003) 9361-9374
48. Ivan M., Kondo K., Yang H., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292 (2001) 464-468
49. Jaakkola P., Mole D.R., Tian Y.M., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
50. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., and Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16 (1997) 3693-3704
51. Jensen R.L., Ragel B.T., Whang K., and Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J. Neurooncol. 78 (2006) 233-247
52. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62 (2002) 7066-7074
53. Kaper F., Dornhoefer N., and Giaccia A.J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 66 (2006) 1561-1569
54. Knowles H.J., Raval R.R., Harris A.L., and Ratcliffe P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63 (2003) 1764-1768
55. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., Fisher R.J., Shoemaker R.H., and Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65 (2005) 9047-9055
56. Koong A.C., Chen E.Y., Lee A.S., Brown J.M., and Giaccia A.J. Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction. Int. J. Radiat. Oncol. Biol. Phys. 28 (1994) 661-666
57. Koritzinsky M., Magagnin M.G., van den Beucken T., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 25 (2006) 1114-1125
58. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., Koromilas A., and Wouters B.G. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol. Cell. Biol. 22 (2002) 7405-7416
59. Kwiatkowski D.J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67 (2003) 87-96
60. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16 (2002) 1466-1471
61. Lang K.J., Kappel A., and Goodall G.J. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol. Biol. Cell 13 (2002) 1792-1801
62. Lanzen J., Braun R.D., Klitzman B., Brizel D., Secomb T.W., and Dewhirst M.W. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res. 66 (2006) 2219-2223
63. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
64. Lazaris-Karatzas A., Montine K.S., and Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345 (1990) 544-547
65. Lee A.H., Iwakoshi N.N., Anderson K.C., and Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U S A 100 (2003) 9946-9951
66. Lee J.T., and McCubrey J.A. BAY-43-9006 Bayer/Onyx. Curr. Opin. Investig. Drugs 4 (2003) 757-763
67. Lejbkowicz F., Goyer C., Darveau A., Neron S., Lemieux R., and Sonenberg N. A fraction of the mRNA 5′ cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus. Proc. Natl. Acad. Sci. U S A 89 (1992) 9612-9616
68. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
69. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., and Shen Y. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 65 (2005) 7249-7258
70. Liu J., Valencia-Sanchez M.A., Hannon G.J., and Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat. Cell. Biol. 7 (2005) 719-723
71. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., and Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21 (2006) 521-531
72. Ljungkvist A.S., Bussink J., Kaanders J.H., et al. Hypoxic cell turnover in different solid tumor lines. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 1157-1168
73. Ljungkvist A.S., Bussink J., Rijken P.F., Kaanders J.H., van der Kogel A.J., and Denekamp J. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 215-228
74. Lu P.D., Harding H.P., and Ron D. Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167 (2004) 27-33
75. Ma X.L., Weyrich A.S., Lefer D.J., and Lefer A.M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. 72 (1993) 403-412
76. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., and Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
77. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., and Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62 (2002) 2478-2482
78. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414 (2001) 550-554
79. Mason S.D., Howlett R.A., Kim M.J., et al. Loss of skeletal muscle HIF-1alpha results in altered exercise endurance. PLoS Biol. 2 (2004) e288
80. Mayer A., Hockel M., and Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin. Cancer Res. 11 (2005) 7220-7225
81. Mizukami Y., Jo W.S., Duerr E.M., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 11 (2005) 992-997
82. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
83. Muss H.B., Blessing J.A., and DuBeshter B. Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am. J. Clin. Oncol. 16 (1993) 492-493
84. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77 (2005) 18-24
85. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41 (1996) 31-39
86. Novoa I., Zeng H., Harding H.P., and Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J. Cell Biol. 153 (2001) 1011-1022
87. Papandreou I., Cairns R.A., Fontana L., Lim A.L., and Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3 (2006) 187-197
88. Papandreou I., Krishna C., Kaper F., Cai D., Giaccia A.J., and Denko N.C. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 65 (2005) 3171-3178
89. Park H.R., Tomida A., Sato S., Tsukumo Y., Yun J., Yamori T., Hayakawa Y., Tsuruo T., and Shin-ya K. Effect on tumor cells of blocking survival response to glucose deprivation. J. Natl. Cancer Inst. 96 (2004) 1300-1310
90. Pelicano H., Carney D., and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 7 (2004) 97-110
91. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
92. Peralba J.M., DeGraffenried L., Friedrichs W., Fulcher L., Grunwald V., Weiss G., and Hidalgo M. Pharmacodynamic Evaluation of CCI-779, an inhibitor of mTOR, in cancer Patients. Clin. Cancer Res. 9 (2003) 2887-2892
93. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., and Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 94 (2006) 195-199
94. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
95. Rapisarda A., Shoemaker R.H., and Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 3 (2004) 172-175
96. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
97. Raval R.R., Lau K.W., Tran M.G., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25 (2005) 5675-5686
98. Romero-Ramirez L., Cao H., Nelson D., et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64 (2004) 5943-5947
99. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., and Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10 (2004) 484-486
100. Ruvinsky I., and Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 31 (2006) 342-348
101. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
102. Sarnow P. Translation of glucose-regulated protein 78/immunoglobulin heavy-chain binding protein mRNA is increased in poliovirus-infected cells at a time when cap-dependent translation of cellular mRNAs is inhibited. Proc. Natl. Acad. Sci. U S A 86 (1989) 5795-5799
103. Schepens B., Tinton S.A., Bruynooghe Y., Beyaert R., and Cornelis S. The polypyrimidine tract-binding protein stimulates HIF-1alpha IRES-mediated translation during hypoxia. Nucleic Acids Res. 33 (2005) 6884-6894
104. Seagroves T.N., Ryan H.E., Lu H., Wouters B.G., Knapp M., Thibault P., Laderoute K., and Johnson R.S. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 21 (2001) 3436-3444
105. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
106. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., and Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 (2004) 91-99
107. Simpson P.J., and Lucchesi B.R. Free radicals and myocardial ischemia and reperfusion injury. J. Lab. Clin. Med. 110 (1987) 13-30
108. Sobhanifar S., Aquino-Parsons C., Stanbridge E.J., and Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 65 (2005) 7259-7266
109. Sonenberg N., and Gingras A.C. The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10 (1998) 268-275
110. Song M.S., Park Y.K., Lee J.H., and Park K. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. Cancer Res. 61 (2001) 8322-8330
111. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
112. Stein I., Itin A., Einat P., Skaliter R., Grossman Z., and Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol. Cell. Biol. 18 (1998) 3112-3119
113. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., and Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006) 122-127
114. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9 (1955) 539-549
115. Vattem K.M., and Wek R.C. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl. Acad. Sci. U S A 101 (2004) 11269-11274
116. Wadler S., Tenteromano L., Cazenave L., et al. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother. Pharmacol. 34 (1994) 266-269
117. Welsh S.J., Williams R.R., Birmingham A., Newman D.J., Kirkpatrick D.L., and Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol. Cancer Ther. 2 (2003) 235-243
118. Wendel H.G., De Stanchina E., Fridman J.S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
119. Wouters B.G., van den Beucken T., Magagnin M.G., Lambin P., and Koumenis C. Targeting hypoxia tolerance in cancer. Drug Resist. Updat. 7 (2004) 25-40
120. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
121. Yoshida H., Matsui T., Yamamoto A., Okada T., and Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107 (2001) 881-891
122. Young J., and Povey S. The genetic basis of tuberous sclerosis. Mol. Med. Today 4 (1998) 313-319